David L. Porter

Chapman University — United States

Medicine · Health Sciences

61h-index33.4kcitations453works8.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(263), Hematopoietic Stem Cell Transplantation(59), Viral Infectious Diseases and Gene Expression in Insects(46), Chronic Lymphocytic Leukemia Research(44), Acute Lymphoblastic Leukemia research(43)

Publications453 total

Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S10 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience
Blood·2025Open Access
Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium
Blood·2025Open Access
Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis
Blood·2025Open Access
Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study
Blood·2025Open Access
Match Stability with a Costly and Flexible Number of Positions
Games·2025Open Access
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
New England Journal of Medicine·2025· 59 cited
A Review of the Taxonomic Status of Hypothyce mixta Howden, 1968 (Coleoptera: Scarabaeidae: Melolonthinae)
The Coleopterists Bulletin·2025
page 1 of 23Next →

Frequent Co-authors

Carl H. June(30), Noelle V. Frey(22), Stephan A. Grupp(19), Simon F. Lacey(18), Bruce L. Levine(18), J. Joseph Melenhorst(17), Saar Gill(13), Shannon L. Maude(10), Stephen J. Schuster(10), David T. Teachey(8), Marco Ruella(8), Sunita D. Nasta(7), Joseph A. Fraietta(7), Elizabeth O. Hexner(7), David M. Barrett(6), Michael Kalos(6), Jakub Svoboda(6), Farzana Nazimuddin(6), Pamela A. Shaw(5), Zhaohui Zheng(5)